A multicenter, randomized, double-blind, placebo-controlled study to evaluate the tolerability and effect of MK0524A [niacin/laropiprant] on niacin-induced acute flushing in lipid clinic patients.

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the tolerability and effect of MK0524A [niacin/laropiprant] on niacin-induced acute flushing in lipid clinic patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Niacin; Niacin/laropiprant
  • Indications Lipid metabolism disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 24 Jul 2009 Planned number of patients changed from 300 to 330 as reported by ClinicalTrials.gov.
    • 06 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top